Trial Profile
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Atezolizumab (Primary) ; Darolutamide (Primary) ; Enzalutamide (Primary) ; Inobrodib (Primary) ; Olaparib (Primary) ; Prednisolone; Prednisone
- Indications Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors CellCentric
- 04 Jun 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 30 Jun 2022 Planned number of patients changed from 250 to 350.
- 30 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Mar 2024.